Scientific Programme

Scientific Programme

Monday 27th

Monday 27th March
9:00 – 13:00 Banff Pre-meeting: New endpoints for Next Generation Clinical Trials
Chairs: Denis Glotz, Peter Nickerson
  • Welcome and opening Remarks: History and Future of the Banff Classification, Where the Present Lesion Scoring Criteria Came From, and the Continued Need for Ease of Use and Time Efficiency
    Kim Solez, Alberta, Canada
  • A tribute to Daniel R. Salomon (1953-2016)
    Kim Solez, Alberta, Canada
  • Next Generation Clinical Trials: how the Banff classification needs to support these
    Kim Solez, Alberta, Canada
  • DSA-monitoring as an end point
    Anat Tambur, Chicago, USA
  • Refined histology scoring as a reliable endpoint
    Bob Colvin, Boston, USA

10:45 – 11:15: Coffee break

  • The Molecular Microscope as an endpoint
    Philip Halloran, Alberta, Canada
  • Clinical trials: the FDA unmet needs
    Mark Stegall, Rochester, USA
  • Potential endpoints for response to treatment of ABMR in heart transplant recipients
    Luciano Potena, Bologna, Italy
13:00 – 14:00 Lunch break
14:00 – 15:00 Industry Symposium 1
15:00 – 17:30 Banff Pre-meeting: New endpoints for Next Generation Clinical Trials
Chairs: Denis Glotz, Peter Nickerson
  • Potential endpoints for response to treatment of ABMR in liver transplant recipients
    Sandy Feng, San Francisco, USA
  • Potential endpoints for response to treatment of ABMR in kidney transplant recipients
    Mark Stegall, Rochester, USA
  • Optimizing Statistical methods for generating robust endpoints
    Dorry Segev, Baltimore, USA
  • Adopting a histo-immuno-clinico-laboratory composite endpoint: The iBox
    Alexandre Loupy, Paris, France
  • Group Discussion
19:00 – 20:00 BANFF BOT MEETING

Tuesday 28th

Tuesday 28th March
9:00 – 13:00 Up-dates from Banff Working Groups
Chairs: Lorrain Racusen, Kim Solez
  • Report on Banff Foundation
    Michael Mengel, Alberta, Canada
  • Proposal for new Banff Working Group: Transplantation HIV+ to HIV+
    Serena Bagnasco, Baltimore, USA
  • EM scoring BWG
    Harsharan Singh, Chapel Hill, USA
  • Highly sensitized BWG
    Carrie Schinstock, Rochester, USA

10:30 – 11:00: Coffee break

  • Recurrent GN BWG
    Nada Alachkar, Baltimore, USA
  • TMA in transplants BWG
    Marjan Afrouzian, Galveston, USA
  • TCMR/borderline BWG
    Parmjeet Randhawa, Pittsburg, USA; and Volker Nickeleit, Chapel Hill, USA
  • Molecular BWG
    Michael Mengel, Alberta, Canada
13:00 – 14:00 Lunch break
14:00 – 15:00 Industry Symposium 2
15:00 – 19:00 Banff Concurrent Sessions: Kidney 1, Lung, Liver 1
Banff Concurrent Kidney 1: The significance of i-IFTA revisiting TCNR and mixed rejection
Chairs: Ian Gibson, Candice Roufosse

  • What defines chronic-active TCMR
    Roz Mannon, Alabama, USA
  • Pathology of mixed rejection
    Ian Gibson, Manitoba, Canada
  • Pathology of the late post-transplant kidney and the role of non T cells
    Lynn Cornell, Rochester, USA
  • Molecular correlates of chronic TCMR
    Enver Akalin, New York, USA

16:30 – 17:00: Coffee break

  • Do we need different scoring rules in early and late allograft biopsies?
    Maarten Naesens, Leuven, Belgium
  • i IFTA: significance and prognostic value
    Clement Gosset, Paris, France
  • Treatment of late and mixed rejection pathology
    Brian Nankivell, Westmead, Australia
  • Group discussion
Banff Concurrent: Lung-Antibody-mediated rejection, to be continued
Chairs: David Hwang and Elizabeth Pavlisko

  • The multidisciplinary approach to AMR in lung transplantation – reaching a consensus
    Deborah Levine, San Antonio, USA
  • Histopathology of AMR in the lung – Part 1
    Fiorella Calabrese, Padova, Italy
  • Histopathology of AMR in the lung – Part 2
    Gerry Berry, Stanford, USA
  • DSAs in lung transplantation
    Adriana Zeevi, Pittsburg, USA

16:30 – 17:00: Coffee break

  • Molecular signals and lung transplantation
    Phil Halloran, Alberta, Canada
  • Relevant endpoints in lung AMR treatment
    Antoine Roux, Paris, France
  • Therapeutic options and strategies – the old and the new
    Ramsey Hachem, Missouri, USA
  • Group discussion
Banff Concurrent Liver 1
Chairs: Anthony Jake Demetris and Stefan Hübscher

  • Introduction – aims of liver sessions
    Anthony Jake Demetris, Pittsburg, USA
  • Pathology of Extra-corporeal perfusion of Liver Allografts – what to examine and how does it correlates with outcome
    Annette Gouw, Groningen, the Netherlands
  • The prospects of extra-corporeal machine perfusion of donor livers
    Robert Porte, Groningen, the Netherlands

16:30 – 17:00: Coffee break

  • Fibrosis and Structural Decline of Liver Allografts: what and how to measure and potential underlying causes
    Carla Venturi Monteagudo, Brussels, Belgium
  • A Pathologists Guide to Evaluating the Long-Surviving Allograft: important features, stains, and approach to better understanding of chronic AMR
    Stefan Hübscher, Birmingham, United Kingdom
  • Group Discussion

Wednesday 29th

Wednesday 29th March
08:30 – 10:00 Banff Plenary 1: The integrated Diagnosis: Histology + DSA
Chairs: Phil Halloran, Christophe Legendre
  • DSA positive and then – To biopsy or not?
    Peter Nickerson, Manitoba, Canada
  • HLA DSA properties assesment in the real life : what does it add?
    Adriana Zeevi, Pittsburg, USA
  • The value of DSA in managing ABMR diagnostic, prognostic, and response to therapy
    Carmen LeFaucher, Paris, France
  • Do we need DSA to diagnose ABMR – the pathologists view?
    Mark Haas, Sherman Oaks, USA
10:00 – 10:30 Coffee break
10:30 – 11:30 SCT Plenary 1: State of the art: Cellular repair of damaged organs
Chairs: Laura Lladó and Kim Solez
  • Cell theraphy in lung diseases
    Anna Serrano Mollar, Barcelona, Spain
  • Cell implantation after myocardial infarction: a 10 years experience from ICREC laboratory
    Santiago Roura, Barcelona, Spain
  • Repopulating scaffoldings in kideny and liver
    Mireia Caralt, Barcelona, Spain
11:30 – 12:00 Joint Welcome Session
12:00 – 13:00 Joint Plenary abstracts 1
Chairs: Ramón Charco and Brian Nankivell
13:00 – 14:00 Industry symposium 3
14:00 – 15:00 Lunch break
15:00 – 16:30 SCT Plenary 2: Key issues in clinical trials in solid organ transplantation
Chairs: Denis Glotz and Frederic Oppenheimer
  • The challenge of therapeutic innovation in organ transplantation
    Josep M. Grinyó, Barcelona, Spain
  • Methodological constraints in the design of clinical trials
    Daniel Serón, Barcelona, Spain
  • New endpoints for New Generation Clinical Trials: A Summary of Banff proposals
    Julio Pascual, Barcelona, Spain
  • Clinical trials investment. The industry point of view
    Guido Junge, Basilea, Switzerland 
16:30 – 17:00 Coffee break
17:00 – 18:30 SCT Oral Session 1: Experimental and Immunology aspects
Chairs: Lluís Guirado and Eduard Palou
15:00 – 18:30 Banff Concurrent Sessions: Pancreas, Heart, VCA
Banff concurrent: Pancreas
Chairs: Cinthia Rachemberg

  • Pancreas perfusion with hypothermic machine: pancreas and duodenal histology up to 24 hours
    Julien Branchereau, Nantes, France
  • Effect of immunosuppressive therapies on transplanted islets and pancreas
    Javier Trinanes Ramos, Leiden, the Netherlands
  • Outcome of pancreas transplantation alone with portal venous drainage vs. systemic venous drainage
    Stephen Bartlett, Baltimore, USA
  • Vascular remodelling following whole pancreas transplantation
    Steven White, New Castle, United Kingdom

16:30 – 17:00: Coffee break

  • Impact of BK infection in pancreas transplant recipients
    Maria Fernanda Toniolo, Buenos Aires, Argentina
  • Histology of refractory rejection
    John Papadimitriou, Maryland, USA
  • Comparison between rejection in pancreas and kidney biopsies in SPK patients with graft dysfunction.
    Pablo Uva, Buenos Aires, Argentina
  • Case presentation
    Diego Cantarovich, Nantes, France
  • Group Discussion
Banff concurrent: Heart
Chairs: Annalisa Angelini, Gerald Berry

  • The contribution of the pathologist to expand the donor pool in cardiac transplantation
    Ornella Leone, Bologna, Italy
  • The multifaceted pathologies of CAV
    Gregory Fishbein, Los Angeles, USA
  • Vasculitis process at the base of CAV
    Marny Fedrigo, Padova, Italy
  • Immunopathology of CAV
    Manon Huibers, Utrecht, the Netherlands
  • Chronic injury to the microcirculation in EMB
    Dylan Miller, Salt Lake City, USA; and Patricia Revello, Salt Lake City, USA

16:30 – 17:00: Coffee break

  • cfDNA in heart transplantation injury to the microcirculation in EMB
    Kiran Krush, Stanford, USA
  • Gene expression on FFPE EMB for the diagnosis of rejection in Heart Transplantation
    Michael Mengel, Alberta, Canada
  • MicroRNA on FFPE EMB for the diagnosis of rejection in Heart Transplantation
    Annalisa Angelini, Padova, Italy
  • Does chronic ABMR exist in cardiac transplantation?
    Patrick Bruneval, Paris, France
  • Towards an uniform terminology for the pathology of CAV
    Gerald Berry, Stanford, USA
  • Panel discussion on CAV terminology/pathophysiology: Towards an uniform terminology for the pathology of CAV
    Discussion leader Gerald Berry, Stanford, USA
Banff concurrent: VCA
Chairs: Linda Cendales, Brand Farris

  • Chronic rejection in VCA
    Jean Kanitakis, Lyon, France
  • VCA skin scoring system in a preclinical model
    Robert Colvin, Boston, USA
  • The role of immunohistochemistry and additional tools in the diagnosis of VCA skin rejection
    David Elder, Philadelphia, USA
  • Skin containing VCA as a monitoring tool for intestinal transplantation
    Annemarie Weissenbacher, Oxford, United Kingdom
  • Uterus transplant rejection: a provisional scoring system for rejection
    Carl Johan Molne, Göteborg, Sweden
  • Vascular changes in a transplanted organ
  • Discussion and Next Steps
18:30 – 19:30 Joint Poster session

Thursday 30th

Thursday 30th March
08:00 – 09:00 Banff Symposium: The Molecular Microscope in routine Transplantation Pathology
Chairs: Mark Haas and Alex Loupy
  • Centralized Molecular diagnostics: Methods, platforms, pitfalls.
    Phil Halloran, Alberta, Canada
  • Decentralized Molecular diagnostics: Pros and Cons.
    Bob Colvin, Boston, USA
  • Panel Discussion
09.00 – 10:30 SCT Plenary 3: How to increase donor pool
Chairs: Julio Pascual and Teresa Pont
  • The changing scenario for organ donation
    Elisabeth Coll, Madrid, Spain
  • Donor quality assessment
    Francesc Moreso, Barcelona, Spain
  • omics to asses quality of donated organs
    Rainer Oberbauer, Vienna, Austria
10:30 – 11:00 Coffee break
11:00 – 12:00 Banff Plenary 2: Staging and Grading of rejection: the need in the era of Precision Medicine
Chairs: Robert Colvin and Philip Halloran
  • IgA Nephropathy:  Morphologic Findings Associated with Disease Progression and Therapeutic Response.  A Working Group Approach
    Mark Haas, Sherman Oaks, USA
  • Grading of microcirculation inflammation in heart allografts
    Jean-Paul Duong Van Huyen, Paris, France
  • Vascularized Allograft biopsies revisited
    Linda Cendales, Durham, USA
12:00 – 13:00 Joint Plenary abstracts 2
Chairs: Josep Maria Cruzado and Michael Mengel
13:00 – 14:00 Industry symposium 4
14:00 – 15:00 Lunch Break
15:00 – 17:30 SCT Plenary 4: Precision medicine in solid organ transplantation
Chairs: Fritz Diekmann, Nicolás Manito
  • Pharmacogenetics to tailor drug exposure and outcomes in kidney transplant
    Dennis Hesselink, Rotterdam, Holand
  • Monitoring memory B Cells responses in transplantation
    Oriol Bestard, Barcelona, Spain
  • State of the art: Finger prints of tolerance
    Maria Hernández, London, United Kingdom

16:00 – 16:30: Coffee Break

  • Personalized medicine in Liver Transplantation
    Miquel Navasa, Barcelona, Spain
  • Measuring patients alloreactivity to personalize treatment
    Merce Brunet, Barcelona, Spain
17:30 – 19:00 SCT Oral Session 2: Update in organ donation
Chairs: David Paredes and Alberto Sandiumenge
15:00 – 19:00 Banff Concurrent Sessions: Kidney 2, Liver 2
Banff concurrent: Kidney 2
Chairs: Mark Haas, Alex Loupy

  • Final decision on PVN scoring
    Volker Nickeleit, Chapel Hill, USA
  • EM scoring system – are we ready for adoption into the classification?
    Candice Roufosse, London, United Kingdom; and Harsharan Singh, Chapel Hill, USA
  • Standardized Banff scoring – A web-based approach
    Jan Ulrich Becker, Cologne, USA

16:00 – 16:30: Coffee break

  • Scoring of i-IFTA: potential rules and role in chronic TCMR
    Parmjeet Randhawa, Pittsburg, USA
  • Group discussion
Banff concurrent: Liver 2
Chairs: Chris Bellamy and Sandy Feng

  • Serum DSA in long-surviving liver allograft recipients: an algorithmic approach to determine potential clinical significance
    Sandy Feng, San Francisco, USA
  • Focusing the “molecular microscopic” on liver allografts: integration of genomics and tissue pathology
    Alberto Sánchez-Fueyo, London, United Kingdom
  • Subclinical liver allograft rejection and “tolerance-related” liver infiltrates
    Richard Taubert, Hannover, Germany

16:00 – 16:30: Coffee break

  • Group discussion
18:30 – 19:30 Joint Poster session

Friday 31st

Friday 31st March
09:00 – 13:00 Banff summary and closing remarks
Chair: Kim Solez
  • Kidney summary
    Mark Haas, Sherman Oaks, USA
  • Liver summary
    Anthony Jake Demetris, Pittsburg, USA
  • Pancreas summary
    Cinthia Drachenberg, Baltimore, USA
  • Heart summary
    Patric Burneval, Paris, France

11:00 – 11:30: Coffee break

  • Lung summary
    David Hwang, Toronto, Canada
  • Vascularized Composite Allografts summary
    Linda Cendales, Durham, USA
  • Closing remarks
    Kim Solez, Alberta, Canada
09:00 – 11:00 SCT Plenary 5: The future of DCD in solid organ transplantation
Chairs: Marta Crespo and Núria Masnou
  • DCD Donors in Spain: pearls and pitfalls
    Elisabeth Coll, Madrid, Spain
  • Risk factors associated with DCD kidney function and survival
    José Maria Portolés Madrid, Spain
  • Will normothermic perfusion become the new standard for the maintenance of DCD donors?
    • Thoracic normothermic perfusion. Steve Large, Cambridge, United Kingdom
    • Abdominal normothermic perfusion. Constantino Fondevila, Barcelona, Spain
  • Update on the results of recent clinical trials on organ machine perfusion prior to transplantation:
    • Lung. Irene Bello, Barcelona, Spain
    • Liver. Rubén Ciria, Córdoba, Spain
    • Kidney
11:00 – 11:30 Coffee break
11:30 – 13:00 SCT Oral Session 3:Hot topics in outcomes after solid organ transplantation
Chairs: Gonzalo Crespo and Antonio Román
13:00 – 13:30 Joint Session Banff-SCT: Gold Medal award of the Catalan Society of Transplantation
Chairs: Antonio Román and Daniel Serón
13:30 – 14:00 Closing